Novartis/Idenix To Co-Promote Hep C Treatment, But Side Effects Delay Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis has exercised its option to license valopicitabine from Idenix in spite of gastrointestinal side effects seen in clinical trials.
You may also be interested in...
Novartis/Idenix Report Mixed Interim Data For Hep C Candidate Valopicitabine
Idenix will await full 72-week data and data from another combination study before deciding the fate of the HCV therapy.
Novartis/Idenix Report Mixed Interim Data For Hep C Candidate Valopicitabine
Idenix will await full 72-week data and data from another combination study before deciding the fate of the HCV therapy.
BIO Panel: Polymerase, Protease Inhibitor Combinations On The Horizon For Hepatitis C
Proof of concept study evaluating polymerase/protease inhibitor combinations for HCV could start within the next year, Vertex predicts.